Aflibercept

Indication

Visual impairment caused by Macular Oedema after branch retinal vein occlusion (NICE TA409)

NICE TA409 - Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion

Red

Brand:

Eylea ®

Nice TA:

409

Commissioning responsibility:

CCG

PbR excluded:

Yes

BNF chapter:

Eye

Background

Aflibercept is recommended as an option within its marketing authorisation for treating visual impairment in adults caused by macular oedema after branch retinal vein occlusion, only if the company provides aflibercept with the discount agreed in the patient access scheme.

Recommendation

LSCMMG Recommendation:

Red

Reason for decision:

Specialist medicine

Supporting documents:

Decisions of Lancashire local decision making groups

BwD	BP	CSR	EL	FW	GP	MB	WL
Red	Red	Red	Red	Red	Red	Red	Red

What do the colours mean?

Last Updated: 01 - Oct - 2016